Professor Mario Campone
Professor Campone, Director General of the Institut de Cancérologie de l’Ouest (ICO) in Angers, France, provides his expert insight into key data presented at ASCO 2018 and what they may mean for optimizing clinical outcomes for patients with advanced breast cancer.
Key topics include:
The place of CDK4/6 inhibitors in relation to endocrine therapy in the treatment sequence for HR+/HER2- advanced breast cancer.
Whether the differing safety profiles of CDK4/6 inhibitors are important when making decisions regarding patient management.
The current challenges for conserving the quality of life of patients with HR+/HER2- advanced breast cancer, compared with managing disease progression.
Whether a broader choice of treatment options may be available in the near future for advanced breast cancer based on the wealth of early phase studies presented at ASCO 2018.
Specific data for advanced breast cancer that were of particular interest for Professor Campone at ASCO 2018, and any implications of these for the management of patients from a national and regional perspective in France.
Clinical Expert Video Series
Watch internationally renowned breast cancer clinicians discussing the latest data from the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5, and what they may mean for clinical practice.
Mario Campone is the CEO of the Institut de Cancérologie de l’Ouest (ICO) since June 2016. He’s a member of several professional organizations including ASCO, EORTC, and ESMO. He earned his doctoral degrees at the University of Nantes. In addition, he holds an LBA in Cell Biology and a Doctorate of University Life Science Discipline and Health. Part of his training was done at the Beatson Institute in Glasgow (UK). Currently, Professor Campone is a hospital practitioner specialist of Medical Oncology in the ICO and Professor of Medical Oncology at the University of Angers. He is responsible for the Phase I unit labelled by the French National Cancer Institute (CLIP 2), and the Head of Breast Cancer and Translational Research at the ICO and interacts with the platforms of transcriptomics (Unité Mixte de Génomique du Cancer) and proteomics, and the Bioinformatics Unit of the ICO.
Professor Campone serves as Chair of the Early Study Group and Vice-Chairman of the Personalized Medicine group of UNICANCER. He integrates the team of 8 led by Dr Juin, Center for Cancer Research and immunology Nantes-Angers UMR-1232 Inserm. The goal of these studies is to identify how aberrant survival contributes to tumour escape and promotes resistance to conventional and targeted therapies, as well as to identify novel targets for innovative treatments. He created the mixed group ORPHEO with the National Veterinary School of Nantes. These activities are to determine the prognostic factors in breast cancer, as well as factors that are predictive of response to targeted therapies.
Professor Campone, has been involved in clinical research since 2003 as both coordinator (26x studies) and Principal Investigator (70x studies) in numerous clinical studies of new agent therapeutic expertise in breast pathology.
Professor Campone is a co-author of over 200 publications in peer-reviewed journals, in the field of cancer and molecular biology. He has obtained two national clinical research hospital programs and one Inca grant in translational research.
Professor Campone was Chairman of the Medical Commission of Establishment (CME) of René Gauducheau Cancer Center from 2005 to 2012. At a national level, he was Chairman of the Early Study Group (2012–2016) and is Vice-President of the Personalized Medicine Group at UNICANCER (since 2015). He is also a founding member of the biotech, OTX (ONCOTHEREX). In the context of personalized medicine, he also has strong involvement in the SyMeTRIC program in the Pays de la Loire, as an expert with the Inca and the National Agency for the Safety of Medicines.
Since November 2015, Professor Campone has been Scientific Director of Cancéropôle Grand Ouest (Bretagne Pays de la Loire and Region Centre). He is also spokesperson for the Cancéropôles conference since 2016. In November 2016, he became President of the Registry of Cancers Loire-Atlantique and Vendée.
Disclosures: Advisory boards for Pfizer, AstraZeneca, Lilly and Novartis. Consultancy for Pierre Fabre and Sanofi. Speaker bureau for Novartis.
ASCO 2018 Highlights